Novo moves into sickle cell with $400M EpiDestiny deal

Novo Nordisk has moved into sickle cell disease through a licensing deal (PDF) with EpiDestiny. The $400 million deal gives Novo worldwide rights to an epigenetic treatment of the disease that is closing in on the start of a phase 2 trial.

• Source: Fiercebiotech
• 707
• April 9, 2018